Stock Update (NYSE:BMY): Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma

[Business Wire] – Bristol-Myers Squibb Company today announced results from CheckMate -025, a Phase 3 study comparing Opdivo to everolimus in advanced renal cell carcinoma after prior anti-angiogenic treatment, showing a significant overall . . . → Read More: Stock Update (NYSE:BMY): Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma Similar Articles: Company Update (NYSE:BMY): European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients Company Update (NYSE:BMY): Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in Previously-Treated Non-Squamous Non-Small Cell Lung Cancer in Pivotal Phase III Trial Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma